bezafibrate has been researched along with Blood Clot in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arai, T; Himeno, S; Kanayama, Y; Kiriyama, K; Manabe, N; Matsuzaki, T; Matsuzawa, Y; Yamane, M; Yamashita, S | 1 |
| Sinzinger, H | 1 |
| McCarty, MF | 1 |
1 review(s) available for bezafibrate and Blood Clot
| Article | Year |
|---|---|
[Antilipemic agents and atherothrombosis. Effects of antilipemic agents on blood platelet function, coagulation and fibrinolysis].
Topics: Anticholesteremic Agents; Antiporters; Arteriosclerosis; Bezafibrate; Blood Coagulation; Blood Coagulation Factors; Blood Platelets; Clinical Trials as Topic; Clofibric Acid; Fenofibrate; Fibrinolysis; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lovastatin; Niacin; Pravastatin; Risk Factors; Simvastatin; Thrombosis | 1998 |
2 other study(ies) available for bezafibrate and Blood Clot
| Article | Year |
|---|---|
Disappearance of intraglomerular lipoprotein thrombi and marked improvement of nephrotic syndrome by bezafibrate treatment in a patient with lipoprotein glomerulopathy.
Topics: Adult; Apolipoprotein E2; Apolipoproteins E; Bezafibrate; Cholesterol, HDL; Female; High-Density Lipoproteins, Pre-beta; Humans; Hypolipidemic Agents; Kidney Diseases; Kidney Glomerulus; Lipoproteins; Lipoproteins, HDL; Nephrotic Syndrome; Thrombosis | 2003 |
Concurrent administration of sustained-release bezafibrate may counteract the increased thrombotic risk associated with oral estrogen therapy.
Topics: Antithrombins; Bezafibrate; Delayed-Action Preparations; Estrogen Replacement Therapy; Female; Humans; Risk Factors; Thrombosis | 2001 |